{"id":296382,"date":"2026-06-23T00:00:00","date_gmt":"2026-06-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0007-2024-biopharma-acute-coronary-syndrome-landscape-forecast-disease-landscape-forecast\/"},"modified":"2026-07-09T11:20:58","modified_gmt":"2026-07-09T11:20:58","slug":"dlsfcv0007-2026-biopharma-acute-coronary-syndrome-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcv0007-2026-biopharma-acute-coronary-syndrome-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Acute Coronary Syndrome &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p class=\"text-align-left\">Acute coronary syndrome (<abbr title=\"acute coronary syndrome\">ACS<\/abbr>) is a leading cause of morbidity and mortality in developed countries. Despite aggressive management of atherothrombotic risk factors through <abbr title=\"low-density lipoprotein cholesterol\">LDL-C<\/abbr> lowering, blood-pressure control, and antithrombotic therapy, post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> patients face a lifelong risk of recurrent ischemic events. This persistent residual risk is driving the expansion of the long-term <abbr title=\"acute coronary syndrome\">ACS<\/abbr> secondary prevention market, with innovation increasingly focused on more intensive lipid management and biomarker-defined treatment of residual risk. Market growth will be driven primarily by continued intensification beyond statins and ezetimibe, including broader use of <abbr title=\"proprotein convertase subtilisin\/kexin type 9\">PCSK9<\/abbr> inhibitors, and selective use of additional oral <abbr title=\"low-density lipoprotein cholesterol\">LDL-C<\/abbr>-lowering agents such as bempedoic acid and obicetrapib. The market will also expand through novel mechanisms that address residual risk beyond traditional factors. <abbr title=\"lipoprotein\">Lp<\/abbr>(a) inhibitors and ziltivekimab will create new add-on opportunities by targeting elevated <abbr title=\"lipoprotein\">Lp<\/abbr>(a) and residual inflammatory risk, respectively. Antithrombotics are not covered in this report.<\/p>\n<p class=\"text-align-left\"><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What factors will drive and constrain the growth of the post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> market?<\/li>\n<li>How will <abbr title=\"lipoprotein\">Lp<\/abbr>(a) inhibitors be clinically positioned, and what is their commercial opportunity?<\/li>\n<li>Will emerging <abbr title=\"proprotein convertase subtilisin\/kexin type 9\">PCSK9<\/abbr> inhibitors expand overall class use, or mainly drive a shift away from evolocumab and alirocumab?<\/li>\n<li>How does bempedoic acid\u2019s positioning differ across the G7 markets?<\/li>\n<li>How do cardiologists perceive obicetrapib\u2019s clinical value and differentiation as an oral <abbr title=\"cholesteryl ester transfer protein\">CETP<\/abbr> inhibitor in a crowded non-statin <abbr title=\"low-density lipoprotein cholesterol\">LDL-C<\/abbr>-lowering landscape?<\/li>\n<li>How do cardiologists expect ziltivekimab to be integrated into post-<abbr title=\"acute coronary syndrome\">ACS<\/abbr> care, and which patients will be selected for treatment?<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Geography<\/strong><\/p>\n<p class=\"text-align-left\">United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p class=\"text-align-left\"><strong>Primary research<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Country-specific interviews with thought-leading cardiologists<\/li>\n<li>Survey data collected for this and other Clarivate research<\/li>\n<\/ul>\n<p class=\"text-align-left\"><strong>Epidemiology<\/strong><\/p>\n<p class=\"text-align-left\">Lifetime diagnosed prevalent cases of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> by country<\/p>\n<p class=\"text-align-left\"><strong>Forecast<\/strong><\/p>\n<p class=\"text-align-left\">10-year, annualized, drug-level sales and patient share of key <abbr title=\"acute coronary syndrome\">ACS<\/abbr> secondary prevention therapies through 2035, segmented by brands \/ generics<\/p>\n<p class=\"text-align-left\"><strong>Drug treatments<\/strong><\/p>\n<p class=\"text-align-left\">Coverage of key current and late-phase emerging therapies<\/p>\n<p class=\"text-align-left\"><strong>Product description<\/strong><\/p>\n<p class=\"text-align-left\">Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296382","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-therapy-areas-cardiovascular","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}